ArticleDrug design, development and therapy2026
Rotenone Inhibited Osteosarcoma Cell Growth Through USP47-Induced Decreases in FEN1 Stability and DNA Integrity.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma (OS) is the most prevalent primary malignant bone tumor in children. We previously showed that rotenone suppressed OS cell metastasis. However, its effects on OS cell growth and the underlying mechanisms remain unclear. The purpose of this study was to investigate the role of rotenone in OS and identify its direct target. Methods: Molecular dockingand Biacore assay were used to confirm the interaction between rotenone and USP47. Co-immunoprecipitation, immunofluorescence, and cycloheximide assays were used to verify the relationship betweenUSP47 and FEN1. Cell cycle and apoptosis were examined by flow cytometry. Comet analyses were used to determine DNA damage. Deubiquination and Ub-VME assays were carried out to assess ubiquitination status and properties. Immunohistochemistry and a xenograft mouse model were utilized to validate the effects of various proteins and rotenone in vivo. Results: Knockdown of FEN1 and USP47 in OS cell lines induced cell cycle arrest and apoptosis through the induction of DNA damage. FEN1 exhibited a direct interaction with USP47. Mechanistically, wild-type USP47 regulated FEN1 protein stability through deubiquitination modification, whereas mutated Cys109Ser USP47 did not. Furthermore, rotenone modulated USP47 protein expression and the combined quantity of Ub-USP47 conjugation through physical interaction. Xenograft studies further confirmed the anti-OS activity of rotenone in vivo. Conclusion: Rotenone is a potential therapeutic agent for OS due to its direct targeting of USP47 and resultant decrease in FEN1 stability and DNA integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.